Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind placebo-controlled study of tulisokibart (MK-7240) in moderate to severe hidradenitis suppurativa
CTR20252479Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tulisokibart in hidradenitis suppurativa (HS), sponsored by Merck & Co.. Started Jul 2025; status: active.
02
Drugs
tulisokibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20252479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252479.